Vitamin D and Phosphate Management Products
OPKO announced on March 4, 2013 that it had acquired all of the assets of Cytochroma, Inc, which form the core of the OPKO Health Renal Division. Cytochroma’s products, currently in Phase 3 clinical development, include a vitamin D compound, Rayaldy™, and a phosphate binder, Alpharen™, for use in chronic kidney disease patients.
OPKO’s proprietary point-of-care vitamin D diagnostic test currently in development will be marketed along with Rayaldy™.
Small Molecule and Biological Therapeutics
OPKO is currently developing several small molecule and biological therapeutics for:
- Protein up-regulation for treatment of various diseases, including cancer, heart disease, metabolic disorders, neurological disorders, and genetic disorders
- Asthma & COPD (chronic obstructive pulmonary disease)
- Parkinson’s disease
- CINV & PONV (chemotherapy-induced nausea and vomiting & post-operative nausea and vomiting)
OPKO is also in the process of developing protein vaccines for influenza.